Effectiveness of glucocorticoid therapy in patients with severe coronavirus disease 2019: Protocol of a randomized controlled trial

Chinese Medical Journal

Volumn 133, Issue 9, 2020, Pages 1080-1086

  Qin, Yuan Yuan ^a   Zhou, Yi Hong ^a   Lu, Yan Qiu ^a   Sun, Feng ^a   Yang, Sen ^a   Harypursat, Vijay ^a   Chen, Yao Kai ^a  

^a CHONGQING PUBLIC HEALTH MEDICAL CENTER   (China)

Author keywords

2019 Novel coronavirus; Acute respiratory distress syndrome; Coronavirus disease 2019; Glucocorticoids; Severe pneumonia

Indexed keywords

METHYLPREDNISOLONE; GLUCOCORTICOID;

ADVERSE EVENT; ARTICLE; ARTIFICIAL VENTILATION; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL PROTOCOL; CONTROLLED STUDY; CORONAVIRUS DISEASE 2019; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HOSPITALIZATION; HUMAN; INCIDENCE; MORTALITY; RANDOMIZED CONTROLLED TRIAL; SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2; STEROID THERAPY; TREATMENT DURATION; BETACORONAVIRUS; CORONAVIRUS INFECTION; DRUG EFFECT; PANDEMIC; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEVERITY OF ILLNESS INDEX; VIRUS PNEUMONIA;

BETACORONAVIRUS; CORONAVIRUS INFECTIONS; GLUCOCORTICOIDS; HUMANS; PANDEMICS; PNEUMONIA, VIRAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEVERITY OF ILLNESS INDEX;

EID: 85083266775     PISSN: 03666999     EISSN: 25425641     Source Type: Journal    
DOI: 10.1097/CM9.0000000000000791     Document Type: Article

References (53)

1. Chen Y, Liu Q, Guo D. Emerging coronaviruses: genome structure, replication, and pathogenesis. J Med Virol 2020;92:418–423. doi: 10.1002/jmv.25681.
2. Zumla A, Chan JF, Azhar EI, Hui DS, Yuen KY. Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov 2016;15: 327–347. doi: 10.1038/nrd.2015.37.
3. WHO. Summary of probable SARS cases with onset of illness from November 1, 2002 to July 31, 2003. WHO, 2003. Available from: https://www.who.int/csr/sars/country/table2004_04_21/en/. [Accessed on February 2, 2020]
4. WHO. Middle East respiratory syndrome coronavirus (MERS-CoV). 2019. Available from: http://www.who.int/emergencies/mers-cov/en/. [Accessed on February 2, 2020]
5. WHO. Novel Coronavirus(2019-nCoV)SITUATION REPORT-121 JANUARY 2020. 2020. Available from: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200121-sitrep-1-2019-ncov.pdf?sfvrsn=20a99c10_4. [Accessed January 20, 2020]
6. WHO. Novel Coronavirus(2019-nCoV) Situation Report – 36 - ERRATUM. 2020. Available from: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200225-sitrep-36-covid-19.pdf?sfvrsn=2791b4e0_2. [Accessed February 25, 2020]
7. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497–506. doi: 10.1016/S0140-6736(20)30183-5.
8. Chan JF, Yuan S, Kok KH, To KK, Chu H, Yang J, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet 2020;395:514–523. doi: 10.1016/S0140-6736(20)30154-9.
9. Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern. Lancet 2020;395:470–473. doi: 10.1016/S0140-6736(20)30185-9.
10. Sung JJ, Wu A, Joynt GM, Yuen KY, Lee N, Chan PK, et al. Severe acute respiratory syndrome: report of treatment and outcome after a major outbreak. Thorax 2004;59:414–420. doi: 10.1136/thx.2003.014076.
11. Wong CK, Lam CW, Wu AK, Ip WK, Lee NL, Chan IH, et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin Exp Immunol 2004;136:95–103. doi: 10.1111/ j.1365-2249.2004.02415.x.
12. Tsang OT, Chau TN, Choi KW, Tso EY, Lim W, Chiu MC, et al. Coronavirus-positive nasopharyngeal aspirate as predictor for severe acute respiratory syndrome mortality. Emerg Infect Dis 2003; 9:1381–1387. doi: 10.3201/eid0911.030400.
13. Arabi YM, Mandourah Y, Al-Hameed F, Sindi AA, Almekhlafi GA, Hussein MA, et al. Corticosteroid therapy for critically ill patients with Middle East respiratory syndrome. Am J Respir Crit Care Med 2018;197:757–767. doi: 10.1164/rccm.201706-1172OC.
14. Chan AW, Tetzlaff JM, Gotzsche PC, Altman DG, Mann H, Berlin JA, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ 2013;346:e7586. doi: 10.1136/ bmj.e7586.
15. Buchman AL. Side effects of corticosteroid therapy. J Clin Gastroenterol 2001;33:289–294. doi: 10.1097/00004836-200110000-00006.
16. National Health Commission of the People’s Republic of China. Guidelines for the Diagnosis and Treatment of Novel Coronavirus (2019-nCoV) Infection by the National Health Commission (Trial Version 6) 2020. Available from: http://www.nhc.gov.cn/yzygj/s7653p/202002/8334a8326dd94d329df351d7da8aefc2/files/b218 cfeb1bc54639af227f922bf6b817.pdf. [Accessed February 18, 2020]
17. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The Third International Consensus definitions for sepsis and septic shock (Sepsis-3). Jama 2016;315:801–810. doi: 10.1001/jama.2016.0287.
18. Lee N, Allen Chan KC, Hui DS, Ng EK, Wu A, Chiu RW, et al. Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients. J Clin Virol 2004;31:304–309. doi: 10.1016/j.jcv.2004.07.006.
19. Liu J, Zheng X, Tong Q, Li W, Wang B, Sutter K, et al. Overlapping and discrete aspects of the pathology and pathogenesis of the emerging human pathogenic coronaviruses SARS-CoV, MERS-CoV, and 2019-nCoV. J Med Virol 2020;1–4. doi: 10.1002/jmv.25709 [E-pub ahead of print].
20. Booth CM, Matukas LM, Tomlinson GA, Rachlis AR, Rose DB, Dwosh HA, et al. Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. JAMA 2003;289:2801–2809. doi: 10.1001/jama.289.21.JOC30885.
21. Yam LY, Lau AC, Lai FY, Shung E, Chan J, Wong V, et al. Corticosteroid treatment of severe acute respiratory syndrome in Hong Kong. J Infect 2007;54:28–39. doi: 10.1016/j.jinf.2006.01.005.
22. So LK, Lau AC, Yam LY, Cheung TM, Poon E, Yung RW, et al. Development of a standard treatment protocol for severe acute respiratory syndrome. Lancet 2003;361:1615–1617. doi: 10.1016/ s0140-6736(03)13265-5.
23. Ho JC, Ooi GC, Mok TY, Chan JW, Hung I, Lam B, et al. High-dose pulse versus nonpulse corticosteroid regimens in severe acute respiratory syndrome. Am J Respir Crit Care Med 2003;168: 1449–1456. doi: 10.1164/rccm.200306-766OC.
24. Lee N, Hui D, Wu A, Chan P, Cameron P, Joynt GM, et al. A major outbreak of severe acute respiratory syndrome in Hong Kong. N Engl J Med 2003;348:1986–1994. doi: 10.1056/NEJMoa030685.
25. Tsang KW, Ho PL, Ooi GC, Yee WK, Wang T, Chan-Yeung M, et al. A cluster of cases of severe acute respiratory syndrome in Hong Kong. N Engl J Med 2003;348:1977–1985. doi: 10.1056/NEJMoa030666.
26. Zhong NS, Zeng GQ. Our strategies for fighting severe acute respiratory syndrome (SARS). Am J Respir Crit Care Med 2003;168:7–9. doi: 10.1164/rccm.200305-707OE.
27. Tsang K, Zhong NS. SARS: pharmacotherapy. Respirology 2003;8 (Suppl):S25–S30. doi: 10.1046/j.1440-1843.2003.00525.x.
28. Stockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment effects. PLoS Med 2006;3:e343. doi: 10.1371/journal. pmed.0030343.
29. Tsang KW, Lam WK. Management of severe acute respiratory syndrome: the Hong Kong University experience. Am J Respir Crit Care Med 2003;168:417–424. doi: 10.1164/rccm.2305012.
30. Wang H, Ding Y, Li X, Yang L, Zhang W, Kang W. Fatal aspergillosis in a patient with SARS who was treated with corticosteroids. N Engl J Med 2003;349:507–508. doi: 10.1056/ NEJM200307313490519.
31. Griffith JF, Antonio GE, Kumta SM, Hui DS, Wong JK, Joynt GM, et al. Osteonecrosis of hip and knee in patients with severe acute respiratory syndrome treated with steroids. Radiology 2005;235: 168–175. doi: 10.1148/radiol.2351040100.
32. Hong N, Du XK. Avascular necrosis of bone in severe acute respiratory syndrome. Clin Radiol 2004;59:602–608. doi: 10.1016/ j.crad.2003.12.008.
33. Lee DT, Wing YK, Leung HC, Sung JJ, Ng YK, Yiu GC, et al. Factors associated with psychosis among patients with severe acute respiratory syndrome: a case-control study. Clin Infect Dis 2004; 39:1247–1249. doi: 10.1086/424016.
34. Tai DY. Pharmacologic treatment of SARS: current knowledge and recommendations. Ann Acad Med Singapore 2007;36:438–443.
35. Who Mers-Cov Research G. State of knowledge and data gaps of Middle East respiratory syndrome coronavirus (MERS-CoV) in humans. PLoS Curr 2013;5. doi: 10.1371/currents.outbreaks.0b-f719e352e7478f8ad85fa30127ddb8.
36. Alfaraj SH, Al-Tawfiq JA, Assiri AY, Alzahrani NA, Alanazi AA, Memish ZA. Clinical predictors of mortality of Middle East respiratory syndrome coronavirus (MERS-CoV) infection: a cohort study. Travel Med Infect Dis 2019;29:48–50. doi: 10.1016/j. tmaid.2019.03.004.
37. Heymann DL. Data sharing and outbreaks: best practice exemplified. Lancet 2020;395:469–470. doi: 10.1016/S0140-6736(20)30184-7.
38. Matthay MA, Zemans RL, Zimmerman GA, Arabi YM, Beitler JR, Mercat A, et al. Acute respiratory distress syndrome. Nat Rev Dis Primers 2019;5:18. doi: 10.1038/s41572-019-0069-0.
39. Bellani G, Laffey JG, Pham T, Fan E, Brochard L, Esteban A, et al. Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries. JAMA 2016;315:788–800. doi: 10.1001/jama.2016.0291.
40. Meduri GU, Bridges L, Shih MC, Marik PE, Siemieniuk RAC, Kocak M. Prolonged glucocorticoid treatment is associated with improved ARDS outcomes: analysis of individual patients’ data from four randomized trials and trial-level meta-analysis of the updated literature. Intensive Care Med 2016;42:829–840. doi: 10.1007/ s00134-015-4095-4.
41. Meduri GU, Golden E, Freire AX, Taylor E, Zaman M, Carson SJ, et al. Methylprednisolone infusion in early severe ARDS: results of a randomized controlled trial. Chest 2007;131:954–963. doi: 10.1378/ chest.06-2100.
42. Meduri GU, Tolley EA, Chrousos GP, Stentz F. Prolonged methylprednisolone treatment suppresses systemic inflammation in patients with unresolving acute respiratory distress syndrome: evidence for inadequate endogenous glucocorticoid secretion and inflammation-induced immune cell resistance to glucocorticoids. Am J Respir Crit Care Med 2002;165:983–991. doi: 10.1164/ ajrccm.165.7.2106014.
43. Meduri GU, Muthiah MP, Carratu P, Eltorky M, Chrousos GP. Nuclear factor-kappaB- and glucocorticoid receptor alpha-mediated mechanisms in the regulation of systemic and pulmonary inflammation during sepsis and acute respiratory distress syndrome. Evidence for inflammation-induced target tissue resistance to glucocorticoids. Neuroimmunomodulation 2005;12:321–338. doi: 10.1159/000091126.
44. Tu GW, Shi Y, Zheng YJ, Ju MJ, He HY, Ma GG, et al. Glucocorticoid attenuates acute lung injury through induction of type 2 macrophage. J Transl Med 2017;15:181. doi: 10.1186/s12967-017-1284-7.
45. Song LC, Chen XX, Meng JG, Hu M, Huan JB, Wu J, et al. Effects of different corticosteroid doses and durations on smoke inhalation-induced acute lung injury and pulmonary fibrosis in the rat. Int Immunopharmacol 2019;71:392–403. doi: 10.1016/j. intimp.2019.03.051.
46. Tongyoo S, Permpikul C, Mongkolpun W, Vattanavanit V, Udompanturak S, Kocak M, et al. Hydrocortisone treatment in early sepsis-associated acute respiratory distress syndrome: results of a randomized controlled trial. Crit Care 2016;20:329. doi: 10.1186/s13054-016-1511-2.
47. Kido T, Muramatsu K, Asakawa T, Otsubo H, Ogoshi T, Oda K, et al. The relationship between high-dose corticosteroid treatment and mortality in acute respiratory distress syndrome: a retrospective and observational study using a nationwide administrative database in Japan. BMC Pulm Med 2018;18:28. doi: 10.1186/s12890-018-0597-5.
48. Seam N, Suffredini AF. Steroids are part of rescue therapy in ARDS patients with refractory hypoxemia: we are not sure. Intensive Care Med 2016;42:924–927. doi: 10.1007/s00134-015-4160-z.
49. Ewald H, Raatz H, Boscacci R, Furrer H, Bucher HC, Briel M. Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV infection. Cochrane Database Syst Rev 2015; CD006150. doi: 10.1002/14651858CD006150ub2.
50. Takaki M, Ichikado K, Kawamura K, Gushima Y, Suga M. The negative effect of initial high-dose methylprednisolone and tapering regimen for acute respiratory distress syndrome: a retrospective propensity matched cohort study. Crit Care 2017;21:135. doi: 10.1186/s13054-017-1723-0.
51. Zhang NF, Li ZR, Wei HY, Liu ZH, Hernigou P. Steroid-induced osteonecrosis: the number of lesions is related to the dosage. J Bone Joint Surg Br 2008;90:1239–1243. doi: 10.1302/0301-620X.90B9.20056.
52. Chan MH, Chan PK, Griffith JF, Chan IH, Lit LC, Wong CK, et al. Steroid-induced osteonecrosis in severe acute respiratory syndrome: a retrospective analysis of biochemical markers of bone metabolism and corticosteroid therapy. Pathology 2006;38:229–235. doi: 10.1080/00313020600696231.
53. Sheng B, Cheng SK, Lau KK, Li HL, Chan EL. The effects of disease severity, use of corticosteroids and social factors on neuropsychiatric complaints in severe acute respiratory syndrome (SARS) patients at acute and convalescent phases. Eur Psychiatry 2005;20:236–242. doi: 10.1016/j.eurpsy.2004.06.023.